Grifols theorized that because ~90% of plasma Aβ is bound to albumin (32), replacing AD patients' plasma with Albutein, which does not contain detectable Aβ (33), should decrease plasma Aβ (34). This evidence concerns the gene ALB and Alzheimer disease.